OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, strengthening the drug developer's intellectual property in ocular inflammatory and pain conditions.
“The issuance of this patent further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation," said CEO Dr Gary Jacobs.
"The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates.”
OK-101 is a chemerin peptide agonist targeting ChemR23 receptors on immune cells in the eye, reducing inflammation. Developed using membrane-anchored-peptide technology, OK-101 offers a long-acting treatment for dry eye disease (DED) and neuropathic corneal pain (NCP).
In a phase II trial, OK-101 demonstrated significant anti-inflammatory and pain-reducing effects. OKYO is preparing for a phase II trial of OK-101 for NCP.